

DAFTAR PUSTAKA

- Agarwal A.K., Raja A., & Brown B.D., 2023, Chronic Obstructive Pulmonary Disease, <https://www.ncbi.nlm.nih.gov/books/NBK559281/>, diakses pada 17 Oktober 2023.
- Agustí, A., Celli, B. R., Criner, G. J., Halpin, D., Anzueto, A., Barnes, P., Bourbeau, J., Han, M. K., Martinez, F. J., Montes de Oca, M., Mortimer, K., Papi, A., Pavord, I., Roche, N., Salvi, S., Sin, D. D., Singh, D., Stockley, R., López Varela, M. V., Wedzicha, J. A., ... Vogelmeier, C. F., 2023, Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary, *American journal of respiratory and critical care medicine*, 207(7), 819–837, <https://doi.org/10.1164/rccm.202301-0106PP>.
- Anderson, J., 2019, *Antibiotic Guidance for Treatment of Acute Exacerbations of COPD (AECOPD) in Adults*, University of Nebraska Medical Center.
- Ansari, S. F., Memon, M., Brohi, N., & Tahir, A., 2019, N-acetylcysteine in the Management of Acute Exacerbation of Chronic Obstructive Pulmonary Disease, *Cureus*, 11(11), e6073. <https://doi.org/10.7759/cureus.6073>
- Anthonisen, N. R., Manfreda, J., Warren, W., Hershfield, S., Harding, G. K. M., & Nelson, N. A., 1987, Antibiotic Therapy in Exacerbations of Chronic Obstructive Pulmonary Disease, *Annals of Internal Medicine*, 106(2), 196, doi:10.7326/0003-4819-106-2-196.
- Appleton, S., Jones, T., Poole, P., Pilotto, L., Adams, R., Lasserson, T. J., Smith, B., Muhammed, J., 2006, Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease, *Cochrane Database of Systematic Reviews*, 2: CD001387.
- Aryal, S., Diaz-Guzman, E., & Mannino, D. M., 2014, Pengaruh jenis kelamin terhadap risiko penyakit paru obstruktif kronik dan hasil pengobatan, *Jurnal Internasional Penyakit Paru Obstruktif Kronik*, 9 , 1145–1154. <https://doi.org/10.2147/COPD.S54476>.
- Barnes, P. J., 2016, Inflammatory mechanisms in patients with chronic obstructive pulmonary disease, *Journal of Allergy and Clinical Immunology*, 138(1), 16-27.
- Bathoorn, E., Groenhouf, F., Hendrix, R., van der Molen, T., Sinha, B., Kerstjens, H. A., Friedrich, A. W., & Kocks, J. W., 2017, Real-life data on antibiotic prescription and sputum culture diagnostics in acute exacerbations of COPD in primary care, *International journal of chronic obstructive pulmonary disease*, 12, 285–290, <https://doi.org/10.2147/COPD.S120510>.
- Belchamber, K. B. R., Thomas, C. M. R., Dunne, A. E., Barnes, P. J., Donnelly, L. E., 2018, Comparison of fluticasone propionate and budesonide on COPD

macrophage and neutrophil function, *International Journal of Chronic Obstructive Pulmonary Disease*, 13, 2883-2897.

Boorsma, M., Lutter, R., van de Pol, M. A., Out, T. A., Jansen, H. M., Jonkers, R. E., 2008, Long-Term Effects of Budesonide on Inflammation Status in COPD, *COPD: Journal of Chronic Obstructive Pulmonary Disease*, 5(2), 97-104.

Bowdish, D. M. E., 2019, The Aging Lung, *CHEST*, 155(2): 391-400.

Cazzola M. & Molimard M., 2010, The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD, *Pulm Pharmacol Ther*, 23(4), 257-67. doi: 10.1016/j.pupt.2010.03.003.

Chatila, W. M., Thomashow, B. M., Minai, O. A., Criner, G. J., & Make, B. J., 2008, Comorbidities in Chronic Obstructive Pulmonary Disease, *Proceedings of the American Thoracic Society*, 5(4), 549–555.

Dipiro, J. T., Dipiro, C.V., Wells, B.G., & Scwinghammer, T.L., 2008, *Pharmacotherapy Handbook Seventh Edition*, McGraw-Hill Company, USA.

Dusser, D., Bravo, M-L., & Lacono, P., 2006, The effect of tiotropium on exacerbations and airflow in patients with COPD, *European Respiratory Journal*, 27(3), 547-555. DOI: <https://doi.org/10.1183/09031936.06.00062705>.

Emir, F., Bansal, V., Gupta, E., Scanlon, P. D., 2016, Association of Inhaled Corticosteroids with Incident Pneumonia and Mortality in COPD; Systematic Review and Meta-Analysis, *COPD: Journal of Chronic Obstructive Pulmonary Disease*, 13(3), 312-326.

Fasitasari, M., 2013, Terapi Gizi pada Lanjut Usia dengan Penyakit Paru Obstruktif Kronik (PPOK), *Sains Medika*, 5(1), 50-61.

Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2023). Executive summary global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.

Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2024). Executive summary global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.

Gosens, R., Zaagsma, J., Meurs, H., Halayko, A. J., 2006, Muscarinic receptor signaling in the pathophysiology of asthma and COPD, *Respiratory Research*, 7(1): 73.

Hillas, G., Perlikos, F., Tsiligianni, I., Tzanakis, N., 2015, Managing comorbidities in COPD, *International Journal of COPD*, 10: 95-109.

Hurst J. R, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas D. A, Agusti A, Macnee W, Calverley P, Rennard S, Wouters E.

- F, Wedzicha J. A., 2010, Susceptibility to exacerbation in chronic obstructive pulmonary disease, *N Engl J Med*, 363(12), 1128-1138, doi: 10.1056/NEJMoa0909883.
- Jenkins, C. R., Chapman, K. R., Donohue, J. F., Roche, N., Tsiligianni, I., Han, M. K., 2017, Improving the Management of COPD in Women, *CHEST*, 151(3), 686-696.
- Joshua J. S. & Thomas P. S., 2015, COPD: Immunopathogenesis and Immunological and BioMarkers, *Advanced in Research*, 3(2), 221-235.
- Kabanga, Y. F. & Haryana, I., 2023, Henti Jantung Mendadak pada Pasien Penyakit Paru Obstruktif Kronis dengan Tuberkulosis Paru : Laporan Kasus, *Pattimura Medical Review*, 5(2), 85-96.
- Kalola, U. K., Ambati, S., 2022, *Budesonide*, StatPearls Publishing, Treasure Island (FL).
- Kemenkes RI, 2013, Riset Kesehatan Dasar (RISKESDAS) 2013, Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kemenkes RI, 2016, Peraturan Menteri Kesehatan Republik Indonesia Nomor 25 Tahun 2016 Tentang Rencana Aksi Nasional Kesehatan Lanjut Usia Tahun 2016-2019, Kemenkes RI, Jakarta.
- Kemenkes RI, 2019, Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/687/2019 Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Penyakit Paru Obstruktif Kronik, Kemenkes RI, Jakarta.
- Khan K.S., Jawaid S, Memon U.A., Perera T, Khan U, Farwa U.E., Jindal U, Afzal M.S., Razzaq W, Abdin Z.U., Khawaja U.A., 2023, Management of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Hospitalized Patients From Admission to Discharge: A Comprehensive Review of Therapeutic Interventions, *Cureus*, 15(8):e43694. doi: 10.7759/cureus.43694.
- Koskela, J., Kilpelainen, M., Kupiainen, H., Mazur, W., Sintonen, H., Boezen, M., Lindqvist, A., Postma, D., Laitinen, T., 2014, Co-morbidities are the key nominators of the health-related quality of life in mild and moderate COPD, *BMC Pulmonary Medicine*, 14: 102.
- Kristiningrum, E., 2019, Farmakoterapi Penyakit Paru Obstruksi Kronik (PPOK), *Cermin Dunia Kedokteran (CDK)*, 46(4), 262-271.
- Li, H., He, G., Chu, H., Zhao, L., Yu, H., 2003, A step-wise application of methylprednisolone versus dexamethasone in the treatment of acute exacerbations of COPD, *Respirology*, 8, 199-204.

- Lundback, B., Lindberg, A., Lindstrom, M., Ronmark, E., Jonsson, A. C., Jonsson, E., Larsson, L. -G., Andersson, S., Sandstrom, T., Larsson, K., 2003, Not 15 But 50% of smokers develop COPD? – Report from the Obstructive Lung Disease in Northern Sweden Studies, *Respiratory Medicine*, 97, 115-122.
- MacLay, J. D., & MacNee, W., 2013, Cardiovascular disease in COPD: mechanisms, *Chest*, 143(3), 798-807, doi: 10.1378/chest.12-0938.
- Mara, Y. A., 2023, Pengaruh Penggunaan Flutikason/Salmeterol Dibandingkan Budesonid/Formoterol Terhadap Kejadian Pneumonia Pada Pasien Penyakit Paru Obstruktif Kronis di RSUP Dr. Sardjito Yogyakarta, *Tesis*, Universitas Gadjah Mada.
- Miravittles, M., 2010, Prevention of exacerbations of COPD with pharmacotherapy, *European Respiratory Review*, 19(116), 119-126. DOI: <https://doi.org/10.1183/09059180.00002810>.
- Miravittles M, Bhutani M, Hurst J.R., Franssen F.M.E., van Boven J.F.M., Khoo E.M., Zhang J, Brunton S, Stolz D, Winders T, Asai K, Scullion J.E., 2023, Implementing an Evidence-Based COPD Hospital Discharge Protocol: A Narrative Review and Expert Recommendations, *Adv Ther*, 40(10), 4236-4263. doi: 10.1007/s12325-023-02609-8.
- Moreno, D., Barroso, J., Garcia, A., 2015, Vaccines for Patients with COPD, *Recent Patents on Inflammation & Allergy Drug Discovery*, 9(1): 23-30.
- Mustofa, S., Hasanah, F. A., Puteri, F. D., Surya, R., Soemarwoto, R. A. S., 2023, Penurunan Kesadaran Disebabkan Gagal Nafas Tipe II pada Pasien Penyakit Paru Obstruktif Kronis (PPOK) Eksaserbasi Akut : Laporan Kasus, *Jurnal Ilmu Kedokteran dan Kesehatan*, 10(6), 2194-2203.
- Nissly, T., & Prasad, S., 2014, PURLs: Should you consider antibiotics for exacerbations of mild COPD?, *The Journal of family practice*, 63(4), E11–E13.
- Ocejo, A., Correa, R., 2022, *Methylprednisolone*, StatPearls Publishing, Treasure Island (FL).
- Oemiati, R., 2013, Kajian Epidemiologis Penyakit Paru Obstruktif Kronik (PPOK), *Media Litbangkes*, 23(2), 82-88.
- Oga, T., Nishimura, K., Tsukino, M., Sato, S., Hajiro, T., Mishima, M., 2003, A Comparison of the Effects of Salbutamol and Ipratropium Bromide on Exercise Endurance in Patients with COPD, *CHEST*, 123(6), 1810-1816.
- Patel, P., Saab, H., Aboeed, A., 2022, *Ipratropium*, StatPearls Publishing, Treasure Island (FL).
- Perhimpunan Dokter Paru Indonesia, 2023, *Pedoman Diagnosis dan Penatalaksanaan Di Indonesia*, PDPI, Jakarta.

- Poole, P. J., & Black, P. N., 2001, Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review, *BMJ (Clinical research ed.)*, 322(7297), 1271–1274. <https://doi.org/10.1136/bmj.322.7297.1271>.
- Poole P, Chong J, & Cates C. J., 2015, Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease, *Cochrane Database of Systematic Reviews*, 29(7), DOI: 10.1002/14651858.CD001287.pub5.
- Primadani, R. G., 2023, Kesesuaian Terapi Pada Pasien Penyakit Paru Obstruktif Kronis Rawat Jalan di RS Khusus Paru Respira Yogyakarta, *Skripsi*, Fakultas Farmasi Universitas Gadjah Mada, Yogyakarta.
- Rothberg M. B, Pekow P. S, Lahti M, Brody O, Skiest D. J, Lindenauer P. K., 2010, Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease, *JAMA*, 303(20), 2035-2042, doi: 10.1001/jama.2010.672.
- Sandman, Z., Iqbal, O. A., 2022, *Azithromycin*, StatPearls Publishing, Treasure Island (FL).
- Senderovich, H., Yendamuri, A., 2019, Management of Breathlessness in Palliative Care: Inhalers and Dyspnea – A Literature Review, *Rambam Maimonides Medical Journal*, 10(1): e0006.
- Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ., 2008, Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD, *Thorax*, 63(7), 592-8. doi: 10.1136/thx.2007.087213.
- Singh D, Agusti A, Anzueto A, Barnes P. J, Bourbeau J, Celli B. R, Criner G. J, Frith P, Halpin D. M. G, Han M, López Varela M. V, Martinez F, Montes de Oca M, Papi A, Pavord I. D, Roche N, Sin D. D, Stockley R, Vestbo J, Wedzicha J. A, Vogelmeier C., 2019, Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019, *Eur Respir J*, 53(5):1900164, doi: 10.1183/13993003.00164-2019.
- Singh, D., Donohue, J. F., Boucot, I. H., Barnes, N. C., Compton, C., Martinez, F. J., 2021, Future concepts in bronchodilation for COPD: dual- versus monotherapy, *European Respiratory Review*, 30: 210023.
- Soeroto, A. Y. & Suryadinata, H., 2014, Penyakit Paru Obstruktif Kronik, *Ina J Chest Crit and Emerg Med*, 1(2), 83-87.
- Vollenweider, D. J., Frei, A., Steurer-Stey, C. A., Garcia-Aymerich, J., & Puhan, M. A., 2018, Antibiotics for exacerbations of chronic obstructive pulmonary disease. *The Cochrane database of systematic reviews*, 10(10), CD010257. <https://doi.org/10.1002/14651858.CD010257.pub2>

- WHO, 2024, Chronic obstructive pulmonary disease (COPD), [https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-\(copd\)](https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)), 18 November 2024.
- Wu, J., & Sin, D.D., 2011, Improved patient outcome with smoking cessation: When is it too late?, *International Journal of COPD*, 6(1), 259-267, 10.2147/COPD.S10771.
- Yang, M., Du, Y., Chen, H., Jiang, D., Xu, Z., 2019, Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials, *Internasional Immunopharmacology*, 77, 105950.
- Yulianti, E., Probosuseno, Ikawati, Z., 2023, Pengaruh Pemberian Inhalasi Budesonid/Formoterol Fumarat Dibandingkan Dengan Flutikason Propionat/Salmeterol Xinafoat pada Rehospitalisasi Pasien Penyakit Paru Obstruktif Kronik di Rumah Sakit Paru Respira, *Majalah Farmaseutik*, 19 (4), 632-641, <https://journal.ugm.ac.id/majalahfarmaseutik/article/view/75256/38498>.
- Yusuf, L. O. M. N. G., 2022, Prevalens Penyakit Paru Obstruktif Kronik Eksaserbasi dengan Komorbid Gagal Jantung : Tinjauan Sistematis dan Meta Analisis, *Tesis*, Universitas Hasanuddin. Diakses melalui https://repository.unhas.ac.id/id/eprint/22920/2/C185172003_tesis_29-07-2022%201-2.pdf.